A study in Health Affairs looks at the potential value of one precision medicine.
New “precision” medicines are being approved with fewer and small trials, which may raise safety questions.
The cost of whole genome sequencing is coming down, but cost, reproducibility, translation and process issues make its routine use for clinical practice unlikely without further refinement and knowledge growth.
Cerner is providing computing and software infrastructure in a partnership with Claritas Genomics to assist providers in the ordering and use of genetic diagnostic tests.http://www.modernhealthcare.com/article/20131205/NEWS/312059958?AllowView=VDl3UXpKSzdDdkdCbkJiYkY0M3hla0dwaWtVZEQrND0=&utm_source=link-20131205-NEWS-312059958&utm_medium=email&utm_campaign=hits&utm_name=top
The FDA has ordered 23andMe to stop selling its personalized genetic testing kits direct to consumers, highlighting the tension between consumer access to their genetic information and the regulatory need to ensure accuracy of tests and govern how the data is interpreted and used.http://medcitynews.com/2013/11/23andme-receives-fda-warning-letter-spit-kits-violation/?utm_source=MedCity+News+Subscribers&utm_campaign=86e7021cf7-RSS_Daily+Top+Stories&utm_medium=email&utm_term=0_c05cce483a-86e7021cf7-67648197
Several articles and commentaries in recent Journal of the American Medical Association issues focus on the role of genomics and personalized medicine in health care.
An article in Nature describes a study of over 1000 individual genomes to identify variation. This is an important step in the continuing evolution of personalized medicine, which is proving to take longer and be more complex that may have initially been imagined.
Yet another brilliant collection of health care data points, including use of gene profiling tests to guide breast cancer care, 30-day mortality models for stroke performance, hospital medication administration errors, the costs of the Medicare physician payment fix and patient-sharing networks among physicians.
It is officially the start of summer and our Potpourri is hot, hot, hot, but not steamy! This week we cover why health care IT doesn’t seem to create productivity gains, the use of whole-genome sequencing, the consequences on failure to comply with prescribed drug regimens and the rates of drug misuse and the potential savings for patients in CDHP plans.